Cognition Therapeutics (CGTX) Equity Average (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Equity Average data on file, last reported at $32.1 million in Q1 2026.

• Quarterly Equity Average rose 106.91% year-over-year to $32.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.1 million (up 106.91% YoY) and the FY2025 annual result came in at $26.5 million, up 22.67% from the prior year.
• Equity Average slipped to $32.1 million in Q1 2026 per CGTX's latest filing, from $35.4 million in the prior quarter.
• Across five years, Equity Average topped out at $50.0 million in Q1 2022 and bottomed at $9.6 million in Q2 2025.
• The 5-year median for Equity Average is $31.7 million (2023), against an average of $30.1 million.
• The widest annual swing landed in 2022, when Equity Average surged 324.49%; it then slumped 62.79% in 2025.
• Tracing CGTX's Equity Average over 5 years: stood at $39.8 million in 2022, then plunged by 32.89% to $26.7 million in 2023, then plunged by 37.77% to $16.6 million in 2024, then jumped by 113.05% to $35.4 million in 2025, then retreated by 9.35% to $32.1 million in 2026.
• Per Business Quant, the three latest CGTX Equity Average figures stand at $32.1 million (Q1 2026), $35.4 million (Q4 2025), and $21.8 million (Q3 2025).

Peer Comparison